Malden, MA, United States of America

Yang Nan

USPTO Granted Patents = 7 


 

Average Co-Inventor Count = 12.5

ph-index = 3

Forward Citations = 25(Granted Patents)


Location History:

  • Lansdale, PA (US) (2013 - 2014)
  • Cambridge, MA (US) (2014)
  • Malden, MA (US) (2010 - 2016)

Company Filing History:


Years Active: 2010-2016

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: Innovations by Inventor Yang Nan in Cancer Treatment

Introduction

Yang Nan, a distinguished inventor based in Malden, MA, has made significant contributions to the field of pharmaceutical sciences with a total of seven patents. His innovative work primarily focuses on developing compounds that serve as inhibitors for the mammalian Target Of Rapamycin (mTOR), a key player in cancer progression and other diseases.

Latest Patents

Among Yang Nan's latest innovations, two notable patents stood out:

1. **Pyrazolo[1,5-a]pyrimidine Compounds as mTOR Inhibitors**: This invention introduces Pyrazolopyrimidine Compounds of Formula (I), which are beneficial in treating cancer and other disorders associated with mTOR deregulation. The present invention also covers pharmaceutically acceptable salts of these compounds.

2. **Fused Tricyclic Compounds as mTOR Inhibitors**: This patent relates to a new class of pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds, also of Formula (I). These compounds serve as inhibitors of mTOR kinase and can be pivotal in the treatment of cancer and other mTOR-related disorders. Additionally, this invention includes pharmaceutical compositions comprising the aforementioned compounds.

Career Highlights

Yang Nan has been associated with prominent pharmaceutical companies, including Merck Sharp & Dohme Corporation and Schering Corporation. His work in these organizations has allowed him to harness his inventive skills and translate his innovative ideas into practical, life-saving solutions.

Collaborations

Throughout his career, Yang Nan has collaborated with esteemed colleagues such as M. Arshad Siddiqui and Yongqi Deng. These collaborations have been instrumental in refining his inventions and pushing the boundaries of pharmaceutical research.

Conclusion

With a robust portfolio of patents and a focus on advancing cancer treatments, Yang Nan continues to leave a lasting impact in the pharmaceutical industry. His innovative approaches hold promise not just for treatment options in oncology but also for broader applications in diseases where mTOR deregulation is a factor.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…